# US 2004/0081998 A1 · Novel carboxylesterase nucleic acid molecules, proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081998 A1
- Document ID: US20040081998A1
- Status: Published application
- Kind: A1
- Application number: 10/678,521
- Filed: 2003-10-02
- Published: 2004-04-29
- Earliest claimed: 1996-11-12
- Inventors: Gary M. Silver; Nancy Wisnewski; Kevin S. Brandt
- Web page: https://patentgrep.com/patent/US20040081998A1

## CPC

- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- A61P 33/12: Schistosomicides
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to arthropod esterase proteins; to arthropod esterase nucleic acid molecules, including those that encode such esterase proteins; to antibodies raised against such esterase proteins; and to other compounds that inhibit arthropod esterase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.

## Claims

### Claim 1

An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74.

### Claim 2

An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:1, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74.

### Claim 3

An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ. ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.

### Claim 4

An isolated protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a nucleic acid molecule selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69, SEQ ID NO:71; and a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:74.

### Claim 5

An isolated flea protein selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences.

### Claim 6

A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to 14% Tris-glycine SDS-PAGE, comprise a fractionation profile as depicted in FIG. 3, wherein said proteins have carboxylesterase activity.

### Claim 7

A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to IEF-PAGE, comprise a fractionation profile as depicted in FIG. 4 in a lane selected from the group consisting of lane 3, lane 4, lane 5, lane 6 and lane 7, wherein said proteins have carboxylesterase activity.

### Claim 8

An isolated flea protein that hydrolyzes α-napthyl acetate to produce α-napthyl, when said protein is incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37° C.

### Claim 9

A formulation comprising flea proteins that hydrolyze α-napthyl acetate to produce α-napthol, when said proteins are incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37° C.

### Claim 10

An isolated flea protein that hydrolyzes the methyl ester group of juvenile hormone to produce a juvenile hormone acid.

### Claim 11

A formulation comprising flea proteins that hydrolyze the methyl ester group of juvenile hormone to produce a juvenile hormone acid.

### Claim 12

A therapeutic composition that, when administered to an animal, reduces hematophagous ectoparasite infestation, said therapeutic composition comprising an excipient and a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of an isolated hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase.

### Claim 13

A method to reduce hematophagous ectoparasite infestation comprising treating an animal with a therapeutic composition comprising a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of a hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase.

### Claim 14

A method to produce a carboxylesterase protein, said method comprising culturing a cell capable of expressing said protein, said protein being encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene.

### Claim 15

A method to identify a compound capable of inhibiting flea carboxylesterase activity, said method comprising:
(a) contacting an isolated flea carboxylesterase with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has carboxylesterase activity; and
(b) determining if said putative inhibitory compound inhibits said activity.

### Claim 16

A test kit to identify a compound capable of inhibiting flea carboxylesterase activity, said test kit comprising an isolated flea carboxylesterase protein having esterase activity and a means for determining the extent of inhibition of said activity in the presence of a putative inhibitory compound.

### Claim 17 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is a flea nucleic acid molecule.

### Claim 18 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla nucleic acid molecules.

### Claim 19 (depends on 1, 2)

The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans nucleic acid molecules.

### Claim 20 (depends on 1, 2)

The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule comprises a Ctenocephalides felis nucleic acid molecule.

### Claim 21 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with a nucleic acid molecule selected from the group consisting of nfE1401, nfE2364, nfE3421, nfE4524, nfE51982, nfE51515, nfE52144, nfE51650, nfE61488, nfE61792, nfE61650, nfE72836, nfE71788, nfE71710, nfE7650, nfE82801, nfE81785, nfE81710, nfE92007, nfE91584, nfE91540, nfE101987 and nfE101590.

### Claim 22 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of nfE1401, nfE2364, nfE3421, nfE4524, nfE51982, nfE51515, nfE52144, nfE51650, nfE61488, nfE61792, nfE61650, nfE72836, nfE71788, nfE71710, nfE7650, nfE82801, nfE81785, nfE81710, nfE92007, nfE91584, nfE91540, nfE101987 and nfE10590.

### Claim 23 (depends on 1, 2)

The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence that encodes a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule encoding a protein having any of said amino acid sequences.

### Claim 24 (depends on 1, 2)

The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76, a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74 SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.

### Claim 25 (depends on 1)

The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises an oligonucleotide.

### Claim 26 (depends on 1, 2)

A recombinant molecule comprising a nucleic acid molecule as set forth in claims 1 or 2 operatively linked to a transcription control sequence.

### Claim 27 (depends on 1, 2)

A recombinant virus comprising a nucleic acid molecule as set forth in claims 1 or 2.

### Claim 28 (depends on 1, 2)

A recombinant cell comprising a nucleic acid molecule as set forth in claims 1 or 2.

### Claim 29 (depends on 2)

The nucleic acid molecule of claim 2, wherein said nucleic acid molecule comprises a nucleic acid sequence that encodes a carboxylesterase protein.

### Claim 30 (depends on 2)

The nucleic acid molecule of claim 2, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with the complement of a nucleic acid sequence encoding said protein.

### Claim 31 (depends on 4)

The protein of claim 4, wherein said protein, when administered to an animal, elicits an immune response against a carboxylesterase protein.

### Claim 32 (depends on 4)

The protein of claim 4, wherein said protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE61792.

### Claim 33 (depends on 4)

The protein of claim 4, wherein said protein is selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41. SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58 SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74.

### Claim 34 (depends on 4)

An isolated antibody that selectively binds to a protein as set forth in claim 4.

### Claim 35 (depends on 6)

The formulation of claim 6, wherein said proteins are selected from the group consisting of proteins having molecular weights ranging from about 60 kD to about 75 kD as determined by 14% Tris-glycine SDS-PAGE.

### Claim 36 (depends on 6)

The formulation of claim 6, wherein said proteins are isolated by the method comprising:
(a) applying soluble proteins of a flea extract to a p-aminobenzamidine agarose bead column;
(b) collecting unbound protein from said p-aminobenzamidine agarose bead column and applying said unbound protein to a gel filtration column;
(c) eluting proteins bound to said gel filtration column and applying said eluted proteins to a cation exchange chromatography column;
(d) eluting proteins bound to said cation exchange column and applying said eluted proteins to an anion exchange chromatography column; and
(e) eluting proteins bound to said anion exchange column with about 170 mM NaCl to obtain said flea carboxylesterase proteins.

### Claim 37 (depends on 7)

The formulation of claim 7, wherein said proteins are selected from the group consisting of proteins having pI values ranging from about pI 4.7 to about pI 5.2 as determined by IEF-PAGE.

### Claim 38 (depends on 8, 9)

The invention of claims 8 or 9, wherein said incubation results in the production of from about 0.3 to at least about 2.5 absorbance units in the presence of Fast Blue when measured at 590 nm.

### Claim 39 (depends on 8)

The protein of claim 8, wherein said protein does not hydrolyze the methyl ester group of juvenile hormone.

### Claim 40 (depends on 8, 9, 10, 11)

The invention of claims 8 or 9 or 10 or 11, wherein the mature form of said protein has a molecular weight ranging from about 60 kD to about 75 kD.

### Claim 41 (depends on 8, 9)

The invention of claims 8 or 9, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and SEQ ID NO:53.

### Claim 42 (depends on 10, 11)

The invention of claims 10 or 11, wherein hydrolyzation of said methyl ester group results in the release of at least about 120 counts per minute of 3H-juvenile hormone acid when determined by the method comprising:
(a) incubating said flea protein in the presence of 3H-juvenile hormone to create a reaction mixture;
(b) combining said reaction mixture with isooctane to produce an aqueous phase and an organic phase;
(c) recovering said aqueous phase; and
(d) determining the amount of 3H-juvenile hormone acid present in said aqueous phase.

### Claim 43 (depends on 10)

The protein of claim 10, wherein said protein does not hydrolyze α-napthyl acetate.

### Claim 44 (depends on 12, 13)

The invention of claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a flea carboxylesterase.

### Claim 45 (depends on 12, 13)

The invention of claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a genus selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla.

### Claim 46 (depends on 12, 13)

The invention of claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a species selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans.

### Claim 47 (depends on 12, 13)

The invention of claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a juvenile hormone esterase.

### Claim 48 (depends on 12, 13)

The invention of claims 12 or 13, wherein said composition further comprises a component selected from the group consisting of an adjuvant and a carrier.

### Claim 49 (depends on 12, 13)

The invention of claims 12 or 13, wherein said composition further comprises a compound that reduces hematophagous ectoparasite burden by a method other than by reducing hematophagous ectoparasite carboxylesterase activity.

### Claim 50 (depends on 12, 13)

The invention of claims 12 or 13, wherein said protective compound is selected from the group consisting of a naked nucleic acid vaccine, a recombinant virus vaccine and a recombinant cell vaccine.

### Claim 51 (depends on 12, 13)

The invention of claims 12 or 13, wherein said inhibitor comprises a substrate analog of a hematophagous ectoparasite carboxylesterase.

### Claim 52 (depends on 13)

The method of claim 13, wherein said animal is selected from the group consisting of adult hematophagous ectoparasites, hematophagous ectoparasite larvae and animals susceptible to hematophagous ectoparasite infestation.

### Claim 53 (depends on 13)

The method of claim 13, wherein said animal is selected from the group consisting of adult fleas, flea larvae and animals susceptible to flea infestation.

### Claim 54 (depends on 13)

The method of claim 13, wherein hematophagous ectoparasite infestation is reduced by hematophagous ectoparasite larvae ingesting adult hematophagous ectoparasite feces comprising said therapeutic composition.

### Claim 55 (depends on 13)

The method of claim 13, wherein said adult hematophagous ectoparasite feces comprises anti-hematophagous ectoparasite carboxylesterase antibodies.

### Claim 56 (depends on 13)

The method of claim 13, wherein anti-hematophagous ectoparasite carboxylesterase antibodies are elicited in a host animal in response to administration of a reagent selected from the group consisting of one or more of said isolated hematophagous ectoparasite carboxylesterase proteins and one or more of said hematophagous ectoparasite carboxylesterase nucleic acid molecules, said adult hematophagous ectoparasite having fed from said host animal after said administration.

### Claim 57 (depends on 13)

The method of claim 13, wherein said animal is selected from the group consisting of mammals and birds.

### Claim 58 (depends on 13)

The method of claim 13, wherein said animal is selected from the group consisting of cats and dogs.

### Claim 59 (depends on 14)

The method of claim 14, wherein said cell expresses a nucleic acid molecule selected from the group consisting of pCro-nfE61488, pTrc-nfE7650, pTrc-nfE71710, pTrc-nfE81710, pTrc-nfE51650, pTrc-nfE91540, pFB-nfE61679, pVL-nfE71802, pVL-fE81792 and pVL-nfE91600.
